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Introduction {#jcsm12148-sec-0004}
============

Doxorubicin has been used extensively for chemotherapy of cancer by the mechanism through which it systemically inhibits cell proliferation *in vivo*. One of the most devastating symptoms associated with mortality of cancer patients during the chemotherapy is development of sarcopenia.[1](#jcsm12148-bib-0001){ref-type="ref"} In humans, survival time in patients who were developed sarcopenia was significantly shorter than in patients who were not developed sarcopenia.[2](#jcsm12148-bib-0002){ref-type="ref"} Doxorubicin has been reported to cause muscle weakness and increase pro‐inflammatory tumour necrosis factor‐alpha (TNF‐alpha) level.[3](#jcsm12148-bib-0003){ref-type="ref"} Evidence from tumour‐free animal study suggests that the sarcopenic effect of doxorubicin is not associated with tumour growth.[1](#jcsm12148-bib-0001){ref-type="ref"}

Muscle size is maintained by a dynamic balance between muscle loss and regeneration. A restoration mechanism to encounter increased entropy of recruited muscle during daily physical challenge is essential, which is currently found to associate with macrophage‐mediated inflammation.[4](#jcsm12148-bib-0004){ref-type="ref"}, [5](#jcsm12148-bib-0005){ref-type="ref"}, [6](#jcsm12148-bib-0006){ref-type="ref"} Macrophage functions to recognize unhealthy cells, activate phagocytosis, regenerate tissue, and finally resolve inflammation.[4](#jcsm12148-bib-0004){ref-type="ref"}, [7](#jcsm12148-bib-0007){ref-type="ref"} Distribution of M1 (CD68^+^) and M2 (CD163^+^) macrophages in inflamed muscle tissue regulates the development of skeletal muscle after damage.[8](#jcsm12148-bib-0008){ref-type="ref"}, [9](#jcsm12148-bib-0009){ref-type="ref"} M1 macrophage is responsible for phagocytic events during early phase of inflammation, and M2 macrophage presents during regenerative phase of inflammation.[4](#jcsm12148-bib-0004){ref-type="ref"}

Q10 is currently considered as an adjuvant option in hope to minimize unwanted side effect during doxorubicin‐based anticancer therapy,[10](#jcsm12148-bib-0010){ref-type="ref"} according to previous results on decreased toxicity of multiple organs during doxorubicin treatment.[11](#jcsm12148-bib-0011){ref-type="ref"}, [12](#jcsm12148-bib-0012){ref-type="ref"} How doxorubicin may influence macrophage distribution during recovery process of eccentric exercise‐challenged skeletal muscle and whether Q10 supplementation can modulate this influence have not yet been examined. Exercise containing eccentric muscle contraction (such as downhill running and resistance exercise) has been shown to cause muscle inflammation,[13](#jcsm12148-bib-0013){ref-type="ref"} which is also known to be an effective way to increase muscle mass during training.[14](#jcsm12148-bib-0014){ref-type="ref"} In this study, we hypothesized that (i) doxorubicin can alter distribution of M1 macrophage and M2 macrophage in skeletal muscle after eccentric exercise; (ii) Q10 supplementation can modulate inflammation, prevent muscle loss, and increase survival rate in doxorubicin‐treated tumour‐free rats.

Methods {#jcsm12148-sec-0005}
=======

Animals {#jcsm12148-sec-0006}
-------

This study was conducted in accordance to guidelines in the care and use of animals conformed to Taiwan government law, and was approved by the Animal Care and Use Committee at University of Taipei (approval number 102001). All Sprague Dawley rats (aged between 4 and 5 months) were obtained from LASCO Corporation (Taipei, Taiwan). Sixty four male Sprague Dawley (SD) rats (body weight 534 ± 5 g) were used for exercise challenge study to trigger muscle inflammation. Fifty six rats (body weight 485 ± 4 g) were used for survival experiment, to determine the protective effect of Q10 on survival during a long‐term doxorubicin treatment. All rats from above studies were evenly allocated into the following four groups: Control (Con), Doxorubicin (Dox), Q10, and Dox + Q10. Two animals were housed per cage with standard laboratory chow (PMI Nutrition International, Brentwood, MO, USA) and tap water *ad libitum*. All animals were kept in an animal room with a 12/12 h light/dark cycle, 23 ± 2 °C and 50% relative humidity for approximately one month until experiment.

Doxorubicin and Q10 {#jcsm12148-sec-0007}
-------------------

To determine the effect of doxorubicin and Q10 on eccentric exercise‐induced muscle inflammation, a dose of doxorubicin (Actavis, Italy SpA., Milano, Italy) at 2.5 mg per kg body weight was intraperitoneal injected according to a method reported elsewhere,[15](#jcsm12148-bib-0015){ref-type="ref"} and a dose of Q10 (PharmaEssentia, Taipei, Taiwan) at 10 mg per kg body weight was orally delivered by stomach tube in solution.[11](#jcsm12148-bib-0011){ref-type="ref"}

Exercise challenge {#jcsm12148-sec-0008}
------------------

Half of rats from each group were challenged to a downhill treadmill running according to previously published methods (Yu *et al.*, 2014). One week prior to experiments, all animals were acclimated to running on a rat treadmill at 10 m/min for 10 min per day. Rats were subjected to an acute bout of intermittent running at a 16° decline. Exercises consisted of 18 sessions (5 min/session) separated by 2 min of rest at 16 m/min for a total of 90 min. An acute dose of doxorubicin or Q10 was delivered 16 h before exercise challenge. Twenty four hours after exercise, rats were anaesthetized with intraperitoneal injection of Zoletil (50 mg per kg body weight). Soleus muscles were surgically collected from both legs and frozen immediately with liquid nitrogen and then stored at −80 °C for further histology, immunohistochemistry (IHC), and western blotting analysis.

Survival experiment {#jcsm12148-sec-0009}
-------------------

Rats were used to determine whether oral Q10 supplementation has beneficial effect for doxorubicin treated rats. Q10 was orally delivered at 0930 am daily, whereas doxorubicin was injected every 3 days. Kaplan--Meier curves were plotted at the end of experiment.

Body composition {#jcsm12148-sec-0010}
----------------

Muscle mass was measured using dual‐energy X‐ray absorptiometry (DXA) (Lunar iDXA, GE Medical Systems, Madison, WI), operated with software version 13.60.033 (encore 2011).

Histology and immunohistochemistry (IHC) {#jcsm12148-sec-0011}
----------------------------------------

Histology and IHC staining were carried out by a professional pathologist at China Medical University Hospital (Taichung, Taiwan). Soleus muscle was fixed in 4% buffered formalin and embedded in paraffin. Tissue sections were cut in 2 to 5 µm slices and transferred onto coated slides (Super Frost Plus, Braunschweig, Germany). Antigen retrieval occurred in boiled water for 15 min in 0.1 M sodium citrate (pH 7.2). These pretreated slides were blocked for 15 min at room temperature with 5% BSA and then incubated at 4 °C overnight with primary antibodies: antibodies against rat CD68 (dilution 1:50) (abcam, Cambridge, UK) and rabbit CD163 (dilution 1:50) (AbD Serotec, Kidlington, UK). Briefly, specific antibody was purchased to perform IHC staining by using horseradish peroxidase‐conjugated avidin biotin complex (ABC) from the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA) and DAB chromogen (Vector Laboratories).[13](#jcsm12148-bib-0013){ref-type="ref"} The sections will be counterstained with haematoxylin and mounted. Inflammation grade was evaluated using a standard semiquantitative scoring system, score 0: none; score 1: giant cells, lymphocytes, plasma cells; score 2: giant cells, eosinophil, neutrophil; score 3: many inflammatory cells, microabscess.

Western blotting analysis {#jcsm12148-sec-0012}
-------------------------

Soleus muscle (\~100 mg) was homogenized in 1 mL of HES buffer containing 20 mM Hepes (Sigma‐Aldrich, St Louis, MO, USA), 1 mM EDTA (Sigma‐Aldrich, St Louis, MO, USA), and 250 mM sucrose (Sigma‐Aldrich, St Louis, MO, USA). Homogenates containing 50 µg of protein were fractionated by SDS‐PAGE (10--12% acrylamide) and transferred to PVDF membranes (PALL Life Science, Ann Arbor, MI, USA) by standard wet transfer methods. After 1 h blocking in PBS containing 5% skim milk, membranes were incubated with primary antibody overnight at 4 °C. Primary antibodies against nitrotyrosine were purchased from Millipore (Bedford, MA, USA) (dilution 1:1000); antibodies against manganese‐dependent superoxide dismutase (MnSOD) (dilution 1:5000) were purchased from Enzo Life Sciences (Ann Arbor, MI, USA); and antibodies against GCS (dilution 1:100) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody‐bound protein was detected using a peroxidase‐conjugated anti‐mouse secondary antibody (Sigma, St Louis, MO, USA) or anti‐rabbit IgG (Cell Signaling Technology, Beverly, MA, USA) and enhanced chemiluminescent HRP substrate (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). To verify equal protein loading, GAPDH (Sigma, St Louis, MO, USA) (dilution 1:5000) was used as an internal control. Western blot bands were quantified using a ChemiDoc™ XRS+ System (BioRad, Hercules, CA, USA).

Quantitative polymerase chain reaction (qPCR) {#jcsm12148-sec-0013}
---------------------------------------------

Total RNA was isolated using Qiagen RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA, USA). Reverse transcription of RNA was carried out using iScript^TM^ cDNA Synthesis Kit (BioRad, Hercules, CA, USA). The following primer and probe sequences were used for amplification of target genes: TNF‐α (NM_012675) forward primer: GAGTCATTGCTCTGTGAG; reverse primer: CTCTGAGGAGTAGACGATA; probe: CTGGCGTGTTCATCCGTTCTCT. IL‐10 (L02926) forward primer: GATCCAGAGATCTTAGCTA; reverse primer: CTGAGGTATCAGAGGTAA; probe: AACCTCGTTTGTACCTCTCTCCAA. TaqMan probes contained a FAM reporter at the 5′‐end and a TAMRA quencher at the 3′‐end. The RT‐qPCR conditions have been previously described.[16](#jcsm12148-bib-0016){ref-type="ref"} Gene relative expression levels were determined by the change in crossing points of reaction amplification (ΔCt value) between targets mRNA and 18S mRNA for each treatment compared with the control group.

Statistical analysis {#jcsm12148-sec-0014}
--------------------

Analysis of variance (ANOVA) was used to compare group difference for all variables. A two‐way ANOVA was used to determine the main effect and interactive effect of treatments. A one‐way ANOVA with a repeated measure was used to compare the mean differences in muscle mass between pre and post during long‐term doxorubicin treatment. Fisher\'s protected least significant test, which holds the value of type I error to 0.05 for each test, was used to distinguish the differences between pairs of groups. A level of *P* \< 0.05 was considered significant on all tests, and all values are expressed as means ± standard errors.

Results {#jcsm12148-sec-0015}
=======

All rats treated with doxorubicin (at dose of 2.5 mg/kg per body weight every 3 days) died within 40 days (*Figure* [1](#jcsm12148-fig-0001){ref-type="fig"}A). No protective effect of Q10 supplementation (10 mg per kg body weight) was found during the entire treatment period. Muscle mass in doxorubicin‐treated rats decreased significantly below those in saline‐injected control rats at Day 14 of the treatment (*Figure* [1](#jcsm12148-fig-0001){ref-type="fig"}B).

![Survival and muscle mass. Q10 supplementation failed to prevent accelerated death (A) and muscle loss (B) of rats during doxorubicin treatment (one injection every 3 days). Doxorubicin treatment resulted in a significant muscle loss in only 14 days, and Q10 supplementation failed to reverse this loss. \* Significant difference against Pre, *P* \< 0.05; † significant difference against Con group, *P* \< 0.05. Abbreviation: Con, Control (*N* = 14); Q10, Coenzyme Q10 (*N* = 14); Dox, Doxorubicin; Q10 + Dox (*N* = 14), Coenzyme Q10 + Doxorubicin (*N* = 14).](JCSM-8-277-g001){#jcsm12148-fig-0001}

An acute bout of downhill running resulted in increases in inflammation score (*Figure* [2](#jcsm12148-fig-0002){ref-type="fig"}A) and necrotic fibres (*Figure* [2](#jcsm12148-fig-0002){ref-type="fig"}B) of soleus muscle, observed 24 h after the challenge. This increase was absent in doxorubicin‐treated exercised rats. Centronucleation (a marker of muscle fibre regeneration) of soleus muscle was not changed in normal rats observed 24 h following eccentric exercise. However, a significant decreased centronucleation of exercised soleus muscle was observed in doxorubicin‐treated rats (*Figure* [2](#jcsm12148-fig-0002){ref-type="fig"}C).

![Muscle inflammation. An acute injection of doxorubicin abolished inflammation of soleus muscle 24 h after eccentric exercise. Inflammation score was determined by pathologist based on haematoxylin and eosin (H&E) staining (A). Score 0: none; score 1: giant cells, lymphocytes, plasma cells; score 2: giant cells, eosinophil, neutrophil; score 3: many inflammatory cells, microabscess. An acute injection of doxorubicin inhibited necrosis (B) and lowered centronucleation (C) of soleus muscle 24 h after eccentric exercise. Representative histochemistry analysis of muscle sections from soleus muscle with H&E staining (Left side of bar chart). Arrowheads indicate leukocyte invasion (B) and centronucleation (C). Nucleolus is labelled with eosin staining (blue colour). Original magnification was 400×, scale bar 50 µm. \* Significant difference against Con group, *P* \< 0.05. Abbreviation: Con, Control; Q10, Coenzyme Q10; Dox, Doxorubicin; Q10 + Dox, Coenzyme Q10 + Doxorubicin.](JCSM-8-277-g002){#jcsm12148-fig-0002}

IHC results on CD68^+^ cell staining show a similar trend to inflammation score among four groups (*Figure* [3](#jcsm12148-fig-0003){ref-type="fig"}A). Exercise increased CD163^+^ cells, but this increase was not depleted in doxorubicin rats (*Figure* [3](#jcsm12148-fig-0003){ref-type="fig"}B). TNF‐alpha mRNAs in non‐exercised soleus muscle of Q10, doxorubicin, and doxorubicin + Q10 groups were significantly increased above saline control group (*Figure* [4](#jcsm12148-fig-0004){ref-type="fig"}A), in the absence of increased leukocyte infiltration. No additive effect of doxorubicin and Q10 on mRNAs of both inflammatory mediators (TNF‐alpha and IL‐10) was found. Exercise increased TNF‐alpha mRNA in muscle of both doxorubicin‐treated and saline‐control rats above non‐exercised control level. Decreased IL‐10 mRNA in exercised muscle below non‐exercised control level occurred in both doxorubicin‐treated and saline‐treated rats (*Figure* [4](#jcsm12148-fig-0004){ref-type="fig"}B). Nitrotyrosine (*Figure* [5](#jcsm12148-fig-0005){ref-type="fig"}A) and GCS (*Figure* [5](#jcsm12148-fig-0005){ref-type="fig"}B) levels of soleus muscle were changed in similar to inflammation score among groups. In particular, exercise‐induced increases in nitrotyrosine and GCS were absent in muscle among doxorubicin‐treated rats. Antioxidant enzyme MnSOD was not different among four groups in both exercised and non‐exercised muscles (*Figure* [5](#jcsm12148-fig-0005){ref-type="fig"}C).

![Macrophage infiltration. Immunohistochemical staining shows a selective depletion of M1 macrophage (CD68^+^) in acute doxorubicin treatment (A) but not M2 macrophage (CD163^+^) (B). \* Significant difference against Con group, *P* \< 0.05. Abbreviation: Con, Control; Q10, Coenzyme Q10; Dox, Doxorubicin; Q10 + Dox, Coenzyme Q10 + Doxorubicin.](JCSM-8-277-g003){#jcsm12148-fig-0003}

![Tumour necrosis factor (TNF)‐alpha and IL‐10 mRNA. Eccentric exercise increased TNF‐alpha mRNA and decreased IL‐10 mRNA of soleus muscle. Q10 and doxorubicin had similar effect on TNF‐alpha mRNA in non‐exercised muscle. \* Significant difference against Con group, *P* \< 0.05; † significant difference against Q10 group, *P* \< 0.05. Abbreviation: Con, Control; Q10, Coenzyme Q10; Dox, Doxorubicin; Q10 + Dox, Coenzyme Q10 + Doxorubicin.](JCSM-8-277-g004){#jcsm12148-fig-0004}

![Protein nitration, manganese‐dependent superoxide dismutase (MnSOD), and gamma‐glutamylcysteine synthetase (GCS). An acute injection of doxorubicin abolished increased in nitrotyrosine (A) and GCS (B) levels of soleus muscle induced by eccentric exercise, but MnSOD remained unaffected by both treatments (C). \* significant difference against Con group, P \< 0.05. Abbreviation: Con, Control; Q10, Coenzyme Q10; Dox, Doxorubicin; Q10 + Dox, Coenzyme Q10 + Doxorubicin.](JCSM-8-277-g005){#jcsm12148-fig-0005}

Discussion {#jcsm12148-sec-0016}
==========

Inflammation is a wound‐healing mechanism in living multicellular organisms.[4](#jcsm12148-bib-0004){ref-type="ref"} During muscle inflammation, macrophages localize in damaged tissues.[9](#jcsm12148-bib-0009){ref-type="ref"}, [17](#jcsm12148-bib-0017){ref-type="ref"} Two subpopulations of macrophage take part during inflammation: (i) the early‐invading, phagocytic macrophages (M1) reaches their highest concentration around 24 h following challenge and rapidly declines in 48 h[9](#jcsm12148-bib-0009){ref-type="ref"}; (ii) the non‐phagocytic macrophage (M2) that are distributed near regenerative fibres for several days. The major finding of this study is the inhibition of exercise‐induced muscle inflammation by an acute dose of doxorubicin administration. IHC staining analysis confirms that M1 macrophage (CD68^+^) was selectively depleted in exercised soleus muscle, 24 h after eccentric exercise challenge. Inability to clear unhealthy muscle fibres in exercised muscle because of M1 macrophage depletion may explain the observed lower ratio of regenerative muscle fibre with doxorubicin treatment. The suppressive effect of doxorubicin on inflammation is further supported by nitrotyrosine data.[18](#jcsm12148-bib-0018){ref-type="ref"} Inhibiting nitric oxide production is expected to decrease stem cell recruitment to damaged tissue during regenerative phase of inflammation,[19](#jcsm12148-bib-0019){ref-type="ref"} which may also contribute to the reduced ratio of regenerative fibres after eccentric exercise.

Doxorubicin is an inhibitor for cell proliferation, which has been widely used to inhibit proliferating tumour cells in cancer patients. Muscle mass is dynamically maintained by a balance of cell death and regeneration. Therefore, systemically inhibition of cell proliferation decreases muscle mass as doxorubicin treatment continues. In adults, cell turnover in muscle tissue is continuously occurring.[20](#jcsm12148-bib-0020){ref-type="ref"} From our centronucleation results, approximately 1.33% of muscle fibre is renewing in eccentrically contracted soleus muscle. An acute dose of doxorubicin injection decreased this percentage to 0.67%. However, the anti‐proliferative action of doxorubicin is non‐specific. Long‐term systemic inhibition on cell proliferation will lead to tissue atrophy to most cell types in the body. Cells with high turnover rate, such as gastrointestinal epithelial cells, will particularly suffer and thus deteriorate nutrient absorption.[21](#jcsm12148-bib-0021){ref-type="ref"} This may add to the devastating consequence of muscle loss during chronic doxorubicin treatment.

Another novel finding of the study is that exercise‐induced increase in TNF‐alpha mRNA and decrease in IL‐10 mRNAs occur in the absence of increased leukocyte infiltration during acute doxorubicin treatment, suggesting that inhibiting leukocyte infiltration to exercised muscle sustains expression of inflammatory mediators in muscle tissue. It is possible that inhibiting cell regeneration by doxorubicin will cause population ageing of cells in muscle tissue. A substantial amount of muscle fibre is renewed during daily life of humans, evidenced by ^14^C DNA measurement of skeletal muscle from two individuals aged 37 and 38 years old exhibiting an actual average muscle age of 15.1 years.[20](#jcsm12148-bib-0020){ref-type="ref"} If cell regeneration mechanism is systemically blocked by doxorubicin, number of aged cell population will accumulate, which leads to increase TNF‐alpha mRNA.[22](#jcsm12148-bib-0022){ref-type="ref"} Doxorubicin has been shown to increase TNF‐alpha mRNA levels of mice heart.[23](#jcsm12148-bib-0023){ref-type="ref"} Inflammation is a process to trigger regeneration when cells produce danger‐associated molecular pattern (likely the aged and unhealthy cells).[24](#jcsm12148-bib-0024){ref-type="ref"} Because no significant increase in leukocyte infiltration in muscle tissue was found, the changes in TNF‐alpha and IL‐10 may simply mirror an imbalance between healthy vs. unhealthy (young vs. old) cell population resided in skeletal muscle caused by doxorubicin.

An unexpected new finding of the study is the increased baseline nitrotyrosine and TNF‐alpha mRNA of skeletal muscle following Q10 supplementation, suggesting that Q10 is pro‐inflammatory to skeletal muscle. However, existing literatures on Q10 supplementation show an attenuated protein nitration level[25](#jcsm12148-bib-0025){ref-type="ref"} under increased oxidative stress induced by ischemic reperfusion and a suppressed TNF‐alpha level in hyperglycemic heart.[26](#jcsm12148-bib-0026){ref-type="ref"} Because none of those previous studies were conducted in normal (unchallenged) physiological condition, we speculate that Q10 may exert a hormesis effect by modulating inflammation to facilitate cell turnover (renewal). We have previously found that pre‐treatment of pro‐inflammatory components of ginseng eliminates exercise‐induced muscle inflammation and protein nitration.[13](#jcsm12148-bib-0013){ref-type="ref"} Furthermore, in this study, we hypothesized that Q10 supplementation can protect animals from lethal action of doxorubicin treatment, based on previous reports demonstrating its benefits on eliminating toxic action of doxorubicin on renal and testicular damage.[11](#jcsm12148-bib-0011){ref-type="ref"} However, the results of current study fail to support this hypothesis.

The major limitation of this study is the lack of mechanistic insight into the role of mitochondria in the doxorubicin‐induced muscle degeneration. Mitochondria dysfunction has been suggested as an underlying cause of doxorubicin‐induced muscle degeneration and weakness.[27](#jcsm12148-bib-0027){ref-type="ref"} Doxorubicin can intercalate into mitochondrial DNA[28](#jcsm12148-bib-0028){ref-type="ref"} that may inhibit mitochondria biogenesis and results in accumulation of aged mitochondria.[29](#jcsm12148-bib-0029){ref-type="ref"} Because mitochondrial turnover occurs at much faster pace compared with normal cells,[30](#jcsm12148-bib-0030){ref-type="ref"} it is possible that increased reactive oxygen species because of accumulation of dysfunctional mitochondria is a cause of catabolic outcome of doxorubicin‐induced muscle atrophy.[31](#jcsm12148-bib-0031){ref-type="ref"}, [32](#jcsm12148-bib-0032){ref-type="ref"}

Previous study in tumour‐free model[1](#jcsm12148-bib-0001){ref-type="ref"} has documented a significant muscle loss during doxorubicin treatment, which is apparently unrelated to tumour growth. Given the fact that muscle loss in both humans and animals are closely associated with increased mortality in both cancer patient[2](#jcsm12148-bib-0002){ref-type="ref"} and elderly,[33](#jcsm12148-bib-0033){ref-type="ref"}, [34](#jcsm12148-bib-0034){ref-type="ref"} development of other adjuvant intervention to preserve muscle mass, other than Q10 supplementation, should be regarded as a primary goal of cancer patients under doxorubicin therapy.

Conclusions {#jcsm12148-sec-0017}
===========

This is the first study demonstrating that doxorubicin blocks muscle inflammation induced by eccentric muscle contraction. Inflammation is crucial for muscle regeneration after physical challenge. Our results provide a new clue to implicate that imbalanced M1 and M2 macrophages in challenged muscle are involved with the development of muscle loss during anti‐proliferation‐based chemotherapy. Furthermore, although Q10 supplementation is pro‐inflammatory to skeletal muscle, it cannot overcome muscle loss and accelerated death under long‐term doxorubicin treatment.
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